Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Northfield Labs PolyHeme Blood Substitute May See FDA Action By Feb 2002

Executive Summary

Northfield Laboratories hopes for action on its BLA for the human-derived hemoglobin substitute PolyHeme by February 2002.

You may also be interested in...



Hollis-Eden Radioprotectant Could Be Accelerated By Military Interest

Hollis-Eden Pharmaceuticals' immune regulating hormone product HE2100 could be approved as a radioprotectant in the next one to three years, Chairman Richard Hollis said

Hollis-Eden Radioprotectant Could Be Accelerated By Military Interest

Hollis-Eden Pharmaceuticals' immune regulating hormone product HE2100 could be approved as a radioprotectant in the next one to three years, Chairman Richard Hollis said

Solvay Ships Phase III Burn Agent To N.Y.; Aventis Sends DT Vaccine

Solvay's investigational burn treatment Flammacerium (sulfadiazine/cerium) will be available to burn victims in New York under a compassionate use program approved by FDA Sept. 12.

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel